Carboplatin-GRY® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUG2 trials

Sponsors

F. Hoffmann-La Roche AG

Conditions

Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)Completely resectedStage Ib (tumors ≥ 4 cm) to Stage IIIaUntreated Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 1

A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination with Other Anti-Cancer Therapies in Patients with Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer with a KRAS G12C Mutation

RecruitingCTIS2023-507171-22-00

F. Hoffmann-La Roche AGUntreated Advanced or Metastatic Non-Small Cell Lung Cancer

Start: 2023-06-21Target: 116Updated: 2025-10-27

Phase 3

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients with Completely Resected Stage Ib (Tumors ≥ 4 Cm) to Stage IIIa Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer

Active, not recruitingCTIS2023-506861-76-00

F. Hoffmann-La Roche AGAnaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC), Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa

Start: 2018-08-09Target: 55Updated: 2025-05-26